Intrapleural Bevacizumab Injection for Treating Malignant Pleural or Pericardial Effusion in Non-small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2017
At a glance
- Drugs Bevacizumab (Primary)
- Indications Malignant pleural effusion; Non-small cell lung cancer; Pericardial effusion
- Focus Therapeutic Use
- 01 Oct 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017.
- 01 Oct 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017.
- 29 Mar 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Jun 2016, according to to ClinicalTrials.gov record.